Previous 10 | Next 10 |
IDEAYA Biosciences (NASDAQ: IDYA ) will collaborate with Pfizer (NYSE: PFE ) on a clinical trial evaluating the combination of IDE196, a protein kinase C inhibitor, and the latter's binimetinib, a MEK inhibitor, in patients with GNA11 hotspot-mutated solid tumors, including metastatic...
SOUTH SAN FRANCISCO, Calif. , March 18, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announces an update for IDE196, a Protein Kinase C...
SOUTH SAN FRANCISCO, Calif. , March 18, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, today announced that it has entered into a clinical tri...
Ideaya Biosciences, Inc. (NASDAQ: IDYA) was featured in a recent equity research report published by ROTH Capital Partners LLC. The report reads, “We are initiating coverage of Ideaya with a Buy rating and $12 PT. Ideaya is a biotech company developing a pipeline of synthetically-lethal...
IDEAYA Biosciences (NASDAQ: IDYA ) initiated with Buy rating and $12 (192% upside) price target at Roth Capital. More news on: IDEAYA Biosciences, Inc., Menlo Therapeutics Inc., Amarin Corporation plc, Healthcare stocks news, Stocks on the move, , Read more ...
SOUTH SAN FRANCISCO, Calif. , March 11, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, today announced an expanded research collaboration...
The following slide deck was published by IDEAYA Biosciences, Inc. in conjunction with this Read more ...
IDEAYA Biosciences (NASDAQ: IDYA ) announces key research highlights from its synthetic lethality pipeline. More news on: IDEAYA Biosciences, Inc., Healthcare stocks news, Read more ...
SOUTH SAN FRANCISCO, Calif. , Jan. 15, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced key research highlights from its synthetic...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks, and our single stock focus. If you are interested in listening to Stocks To Wat...
News, Short Squeeze, Breakout and More Instantly...
IDEAYA Biosciences Inc. Company Name:
IDYA Stock Symbol:
NASDAQ Market:
IDEAYA Biosciences Inc. Website:
IDEAYA Biosciences Announces Option and License Agreement for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program with Biocytogen PR Newswire Option for an exclusive worldwide license for potential first-in class B7H3/PTK7 topo-I-payload bispecific antibod...
Biocytogen granted IDEAYA an option for an exclusive worldwide license for potential first-in-class B7H3/PTK7 topo-I-payload bispecific antibody drug conjugate (BsADC) program B7H3/PTK7 co-expression found in multiple solid tumor types, including double-digit percent prevalence in lung, color...
IDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations Event PR Newswire SOUTH SAN FRANCISCO, Calif. , July 29, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery an...